GEN Exclusives

More »

The Lists

More »
Mar 5, 2013

Top 20 Best-Selling Drugs of 2012

Which drugs were the biggest hits last year?

Top 20 Best-Selling Drugs of 2012

These medications topped the list of money-makers last year. [© grandeduc - Fotolia.com]

  • What makes a drug a success? Is it a great ad campaign, or promotions from doctors? Does the drug address a much-needed area of medicine, or treat a disease in an exceptional way with few side effects? Regardless of what makes a drug take off, the way to measure its overall success is hard to repute: sales.

    GEN updates their list of the best-selling drugs of the 21st century with the top 20 best-selling prescription drugs worldwide of 2012, based on sales figures released by biopharma companies in press announcements, annual reports, and conference calls during 2012 and 2011. Drugs are ranked by 2012 sales. CER denotes “constant exchange rate.”

  • #20. Truvada (emtricitabine and tenofovir disoproxil fumarate)

    Drug maker: Gilead Sciences

    Indication(s): HIV-1 infection in patients aged 12 years and older, in combination with other anti-HIV-1 medicines; also used in pre-exposure prophylaxis with safer sex practices to reduce HIV-1 risk in men who have sex with men at high risk of getting infected with HIV-1 through sex, and heterosexual couples where one partner has HIV-1 and the other does not

    2012 sales: $3.181 billion

    2011 sales: $2.875 billion

    % Change: 10.6%

    Q4 2012 sales: $832 million, up 11.5% from $746 million in Q4 2011

  • #19. Symbicort (budesonide and formoterol)

    Drug maker: AstraZeneca

    Indication(s): Asthma deemed untreatable via long-term asthma control medicine, or deemed sufficiently severe, in patients aged 12 years and older; COPD, including chronic bronchitis and emphysema, in adults

    2012 sales: $3.194 billion

    2011 sales: $3.148 billion

    % Change: 5% at CER

    Q4 2012 sales: $891 million, up 8% from $839 million in Q4 2011

  • #18. Atripla (efavirenz, emtricitabine, and tenofovir)

    Drug maker: Gilead Sciences

    Indication(s): HIV-1 infection in patients aged 12 years and older who weigh at least 40 kg (88 lbs)

    2012 sales: $3.574 billion

    2011 sales: $3.225 billion

    % Change: 10.8%

    Q4 2012 sales: $917 million, up 6.3% from $863 million in Q4 2011

  • #17. Singulair (montelukast)

    Drug maker: Merck & Co.

    Indication(s): Chronic asthma in patients aged 12 months and older; acute prevention of exercise-induced bronchoconstriction in patients aged 6 years and older; allergic rhinitis; seasonal allergic rhinitis in patients aged 2 years and older; and perennial allergic rhinitis in patients 6 months of age and older

    2012 sales: $3.853 billion

    2011 sales: $5.479 billion

    % Change: -29.7%

    Q4 2012 sales: $480 million, down 67.1% from $1.461 billion in Q4 2011

  • #16. Nexium (esomeprazole)

    Drug maker: AstraZeneca

    Indication(s): Four- to eight-week treatment of erosive esophagitis; maintenance of healing of erosive esophagitis; Four- to eight-week treatment of gastroesophageal reflux disease or GERD; NSAID-associated gastric ulcers in at-risk patients, such as adults over age 60, or with a medical history of such ulcers

    2012 sales: $3.944 billion

    2011 sales: $4.429 billion

    % Change: -10% at CER

    Q4 2012 sales: $1.047 billion, down 1% at CER from $1.067 billion

  • #15. Lipitor (atorvastatin calcium)

    Drug maker: Pfizer

    Indication(s): LDL cholesterol and triglyceride reduction in blood as adjunct therapy to diet; reduction of risks for chest pain, stroke, heart attack, or heart and blood vessel problems in people who have certain risk factors

    2012 sales: $3.948 billion

    2011 sales: $9.577 billion

    % Change: -58.8%

    Q4 2012 sales: $584 million, down 70.8% from $1.999 billion in 2011

  • #14. Januvia (sitagliptin)

    Drug maker: Merck & Co.

    Indication(s): Once-daily type 2 diabetes treatment

    2012 sales: $4.086 billion

    2011 sales: $3.324 billion

    % Change: 22.9%

    Q4 2012 sales: $1.134 billion, up 18.1% from $960 million in Q4 2011

  • #13. Lyrica (pregabalin)

    Drug maker: Pfizer

    Indication(s): Fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain, and pain after shingles

    2012 sales: $4.158 billion

    2011 sales: $3.693 billion

    % change: 12.6%

    Q4 2012 sales: $1.132 billion, up 13.4% from $998 million in Q4 2011

  • #12. Neulasta (pegfilgrastim)

    Drug maker: Amgen1

    Indication(s): Neutropenia caused by cancer chemotherapy

    2012 sales: $4.092 billion

    2011 sales: $3.952 billion

    % Change: 3.5%

    Q4 2012 sales: $994 million, down 0.4% from $998 million in Q4 2012

  • #11. Plavix (clopidogrel)

    Drug maker: Sanofi and Bristol-Myers Squibb

    Indication(s): Acute coronary syndrome, recent myocardial infarction, recent stroke, or established peripheral arterial disease

    2012 sales: $5.318 billion—$2.771 billion (Sanofi; €2.066 billion) + $2.547 billion (BMS)2

    2011 sales: $9.823 billion—$2.736 billion (Sanofi; €2.040 billion) + $7.087 billion (BMS)2

    % change: -45.9%

    Q4 2012 sales: $723.1 million—$674.1 million (Sanofi; €503 million) + $49 million (BMS) in Q4 2012. Down 69.6% from $2.381 billion—$708.5 million (Sanofi; €529 million) plus $1.672 billion (BMS) in Q4 20112


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?